Clinical trial

A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)

NCT02497001

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-08-10

PhasePHASE3

Study timeline

Study start (actual)2015-08-10Date precision: day

Registry last updated2020-12-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

COPDunresolved

Interventions

BGF MDI 320/14.4/9.6 μgDRUG

GFF MDI (PT003) 14.4/9.6 μgDRUG

BFF MDI (PT009) 320/9.6 μgDRUG

Symbicort® Turbuhaler® (TBH) Inhalation PowderDRUG

Sponsors & collaborators

Pearl Therapeutics, Inc.lead sponsor

Mapped research locations

KyotoJapan5 BeijingChina4 ShanghaiChina4 GuangzhouChina4 CincinnatiOhio, United States3 MiamiFlorida, United States2 ColumbusOhio, United States2 MinneapolisMinnesota, United States2 RichmondVirginia, United States2 ChangshaChina2 St LouisMissouri, United States1 TorontoOntario, Canada1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02497001 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.